Boehringer changes candidate in Zealand collaboration and delays project by one year
German Boehringer Ingelheim has changed the focus of clinical studies in a million-dollar collaboration with Zealand Pharma. It delays the project and the potential milestone payments for the Danish biotech company. At the same time, Zealand postpones one of its own phase III programs.
Recently, Zealand Pharma sold the rights to payments from Sanofi for two marketed diabetes products, but the Danish company maintains its two collaboration deals with German drug group Boehringer Ingelheim, which can potentially bring in billions to Zealand in future.
Allerede abonnent?Log ind her
Læs hele artiklen
Få adgang i 14 dage for 0 kr. Det kræver intet kreditkort, og du vil ikke overgå til et betalt abonnement efterfølgende.
Med din prøveperiode får du:
Få fuld adgang til dig og dine kollegaer
Start et gratis virksomhedsprøveabonnementRelaterede artikler
New candidates in Zealand’s peptide pipeline
For abonnenter
